Form 4: Vir Biotechnology CEO Marianne De Backer Sells Shares to Cover Tax Obligations

Marianne De Backer, CEO of Vir Biotechnology, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 3, 2025, Marianne De Backer, CEO of Vir Biotechnology, sold 79,712 shares of common stock at a price of $5.9494 per share.
• The sale was executed to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• Following the transaction, De Backer directly owns 769,505 shares and indirectly owns 53,118 shares through the Ureel-De Backer Family Trust.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock sales for tax purposes. It doesn't inherently indicate positive or negative sentiment, but rather a routine financial transaction.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Sales to cover tax obligations are common and don't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, Vir Biotechnology, Marianne De Backer, stock sale, tax obligations, restricted stock units, beneficial ownership